Trial Profile
Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 16 Nov 2023 Status changed from active, no longer recruiting to completed.
- 13 Jun 2023 Planned End Date changed from 30 Nov 2022 to 1 Aug 2023.
- 17 Oct 2022 Planned End Date changed from 30 Nov 2021 to 30 Nov 2022.